NHS
Black Country
Integrated Care Board

# Prescribing Support Information

## *Rimegepant*

***For the acute treatment of migraine with or without aura in adults (18 years and over)***

***Formulary Status – Green***

| **Introduction** | |
|---|---|
| **Enter Drug name** | **Rimegepant** |
| **Enter Proprietary name** | **Vydura** |
| **Enter Formulation and strength** | Oral lyophilizate (75mg)<br>Rimegepant (Vydura) is available in 2 pack sizes: packs of 2 or packs of 8. |
| General Statement<br>**Rimegepant** is classed as **Green** by the Black Country Joint Formulary Group, prescribing is suitable for initiation and maintenance by primary and secondary care clinicians. This medication should be initiated and prescribed within its licensed indications and per NICE TA.<br><br>The information contained in this document is to support you to prescribe Rimegepant for your patient in the community. | |
| Who will diagnose and decide which patients are suitable for this drug? | The prescribing clinician in primary or secondary care in line with NICE TA 919 - Rimegepant for treating migraine. |
| Who will increase the dose? | N/A |
| When will patients prescribed this drug be suitable for discharge to primary care? | N/A this drug can be initiated and continued in primary care. Advice and Guidance can be sought from neurology/headache team (see – contact details of specialist for advice). |
| Who will follow up the patients and how often? | Patient should be reviewed by the initiating clinician by 12 weeks to assess effectiveness and safety of treatment with Rimegepant. |
| Related NICE guidance | NICE TA 919 - Rimegepant for treating migraine<br>https://www.nice.org.uk/guidance/ta919 |
| | |
| **Prescribing Information** | |
| **Indications** | Rimegepant is indicated for the acute treatment of migraine with or without aura in adults. |



ALHAVI
Pharmaceuticals

| | |
|---|---|
| | NICE TA919 recommends Rimegepant as an option for the acute treatment of migraine with or without aura in adults, only if for previous migraines:<br>• at least 2 triptans were tried and they did not work well enough or<br>• triptans were contraindicated or not tolerated, and nonsteroidal anti-inflammatory drugs (NSAIDs) and paracetamol were tried but did not work well enough.<br><br>See Flowchart below for Acute Migraine Treatment Pathway.<br><br>It is also indicated for preventive treatment of episodic migraine in adults who have at least 4 migraine attacks per month (see Rimegepant – Prescribing Support Information for Prevention of Migraine) |
| **Dosage and Route of administration** | **Treatment of acute migraine in adults**<br>The recommended dose of rimegepant is 75 mg, as needed, once daily by mouth.<br>The maximum dose per day is 75 mg.<br>Another dose of rimegepant should be avoided within 48 hours when concomitantly administered with certain interacting medicines, see interactions section below.<br><br>Initial supplies should be restricted to 4 tablets per patient on a trial basis.<br>For acute prescribing only, no repeat prescribing until efficacy and individual patient need can be established. See Flowchart below for Acute Migraine Treatment Pathway. |
| **Relevant Contraindications** | Hypersensitivity to the active substance or to any of the excipients.<br><br>*Please see the Summary of Product Characteristics on VYDURA 75 mg oral lyophilisate - Summary of Product Characteristics (SmPC) - (emc)] for a complete list.* |
| **Relevant Precautions** | Rimegepant is not recommended:<br>- in patients with severe hepatic impairment.<br>- in patients with end-stage renal disease (CrCl < 15 ml/min).<br>- for concomitant use with strong inhibitors of CYP3A4.<br>- for concomitant use with strong or moderate inducers of CYP3A4.<br><br>Pregnancy - Limited data, as a precautionary measure it is preferable to avoid the use of Rimegepant during pregnancy.<br>Breast-feeding - There are no data on the effects on milk production. The mother's clinical need for rimegepant whilst breastfeeding should be weighed against any potential adverse reactions on the breastfed infant. |

| | |
|---|---|
| | Please note:<br>There is limited experience with rimegepant in patients aged 65 years or older. No dose adjustment is required as the pharmacokinetics of rimegepant are not affected by age.<br><br>Patients with significant CV risk were excluded from the clinical trials, hence there is a lack of data upon use in such patients, therefore caution is advised.<br><br>*Please see the Summary of Product Characteristics on* VYDURA 75 mg oral lyophilisate - Summary of Product Characteristics (SmPC) - (emc)*] for a complete list.* |
| **Adverse Events and action to be taken** | This is a Black Triangle drug – all suspected adverse reactions should be reported directly to the MHRA via the Yellow Card Scheme in order to identify rare adverse effects.<br>The most common adverse reaction was nausea for acute treatment (1.2%).<br>Most of the reactions were mild or moderate in severity.<br>Hypersensitivity, including dyspnoea and severe rash, occurred in less than 1% of patients treated.<br>Hypersensitivity reactions, including dyspnoea and rash, can occur days after administration. If a hypersensitivity reaction occurs, Rimegepant should be discontinued.<br><br>*Please see the Summary of Product Characteristics on[*VYDURA 75 mg oral lyophilisate - Summary of Product Characteristics (SmPC) - (emc)*] for a complete list.* |
| **Clinically relevant medicine interactions and their management** | Rimegepant is a substrate of CYP3A4, P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) efflux transporters.<br>CYP3A4 inhibitors increase plasma concentrations of Rimegepant. Another dose of rimegepant within 48 hours should be avoided when it is concomitantly administered with moderate inhibitors of CYP3A4.<br>CYP3A4 inducers decrease plasma concentrations of Rimegepant, which may lead to loss of efficacy.<br><br>*Please see the Summary of Product Characteristics on* VYDURA 75 mg oral lyophilisate - Summary of Product Characteristics (SmPC) - (emc)*] for a complete list* |
| **Required Monitoring and actions to be taken** | Monitor effectiveness of treatment following initiation. Review number of prescriptions issued regularly as patients might need prophylaxis treatment to reduce the number of acute migraines (See prevention of migraine flow chat in prescribing support information sheet: Rimegepant for prevention of migraine). |



| | |
|---|---|
| **When should the drug be stopped?** | There are no formal stopping criteria for this indication but consideration to stop should be made if there is no response after 2-3 attacks or significant side effects. |
| **When to seek Specialist advice/review** | If Rimegepant is either ineffective or intolerable and other oral treatment options have been exhausted. See guidance below. |
| **Contact details of specialist for advice** | Advice and Guidance via choose and book or ERS |
| **Patient Information** | Patients or their carers should be given advice on how to administer Rimegepant oral lyophilisates.<br><br>Rimegepant oral lyophilisates should be placed on or under the tongue and allowed to dissolve. It will disintegrate in the mouth and can be taken without liquid.<br>Rimegepant can be taken with or without meals.<br><br>**Non pharmaceutical and lifestyle advice**<br>Encourage a routine with regular meals, adequate hydration with water, sleep, and exercise.<br>Keep a headache diary (see resources).<br>Avoid triggers if possible.<br>Consider activities that encourage relaxation such as mindfulness or meditation. |
| **Guidance for GP prescribing/Additional Information** | See Treatment pathway for Acute Migraine (Appendix 1)<br><br>Concomitant use of Rimegepant with triptans for treatment of acute migraine is not recommended.<br><br>Headache diary templates:<br>Keeping a headache diary - The Migraine Trust<br>Headache Diary - National Migraine Centre<br><br>Other resources:<br>Scenario: Adults \| Management \| Migraine \| CKS \| NICE<br>Acute medicines for migraine - The Migraine Trust<br>BASH national guidelines at headache.org.uk. BASH Guideline - Headache UK |
| **References** | 1. Summary of product characteristics https://www.medicines.org.uk/emc/product/13928 accessed 16/12/2024.<br>2. BNF https://bnf.nice.org.uk/drugs/rimegepant/ accessed 16/12/2025.<br>3. NICE TA919: Rimegepant for treating migraine [TA919] Published: 18 October 2023 https://www.nice.org.uk/guidance/ta919 accessed |



ALHAVI Pharmaceuticals

| | |
|---|---|
| | 16/12/2024. 4. British Association for the Study of Headache (BASH) - National Headache Management System for Adults 2019 https://bash.org.uk/guidelines/ accessed 16/12/2024 |

## Appendix 1 - Treatment pathway for Acute Migraine

**Treatment Pathway for Acute Migraine:**